Abstract
Abstract
Objective
To determine the effect of opioid and stimulant Risk Mitigation Guidance (RMG) dispensations on mortality and acute care visits during the dual public health emergencies of overdose and covid-19.
Design
Population based retrospective cohort study.
Setting
British Columbia, Canada.
Participants
5882 people with opioid or stimulant use disorder who received RMG prescriptions for opioids (n=5356) and/or stimulants (n=1061) (535 received both) from 27 March 2020 to 31 August 2021.
Main outcome measures
All cause and overdose specific mortality and acute care visits in the week after RMG opioid or stimulant dispensation. RMG recipients were matched 1:1 with controls through use of high dimensional propensity score matching. Marginal structural models, executed on weekly time steps, were used to measure the effect of dispensations on outcomes.
Results
RMG opioid dispensations of one day or more were associated with reduced all cause mortality (adjusted hazard ratio 0.39, 95% confidence interval 0.25 to 0.60) and overdose related mortality (0.45, 0.27 to 0.75) in the subsequent week. Dispensations of RMG stimulants (≥1 days) were not significantly associated with reduced all cause mortality (adjusted hazard ratio 0.50, 0.20 to 1.23) or overdose related mortality (0.53, 0.18 to 1.56). The protective effect of RMG opioid dispensations increased with the number of days the medications were dispensed in a given week. People who received four or more days of RMG opioid dispensations had reduced all cause mortality (adjusted hazard ratio 0.09, 0.04 to 0.21) and overdose related mortality (0.11, 0.04 to 0.32) compared with the control group. Opioid RMG dispensations did not significantly modify the odds of all cause or overdose related acute care visits. Dispensations of RMG stimulants were associated with a significant decrease in the odds of acute care visits for any cause but did not affect the odds of overdose related acute care visits.
Conclusions
RMG opioid dispensations were associated with reduced overdose related and all cause mortality among a sample of people with opioid use disorder. Pharmaceutical alternatives to the illegal drug supply are promising interventions to reduce mortality in people with opioid use disorder.
Funder
National Institutes of Health
Reference50 articles.
1. The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose-related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data
2. Increases in drug overdose deaths in Norway and the United States during the COVID-19 pandemic
3. Public Health Agency of Canada. Opioid- and Stimulant-related Harms in Canada. 2023. https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/.
4. National Center for Health Statistics. U.S. Overdose Deaths In 2021 Increased Half as Much as in 2020 - But Are Still Up 15%. 2022. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm.
5. National Center for Health Statistics. Vital Statistics Rapid Release: Provisional Drug Overdose Data. 2023. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献